

Additional file 7. Baseline pulmonary microbiological findings and therapy in patients with isolated pulmonary *Candida spp.* colonization without pre-existing pneumonia (cohort 2).

	Antifungal therapy (n=44)	No antifungal therapy (n=131)	p-value
<i>Candida spp.</i>, n (%)			
<i>albicans</i>	30 (68.2%)	112 (85.5%)	0.015
<i>glabrata</i>	7 (15.9%)	20 (15.3%)	1
<i>tropicalis</i>	4 (9.1%)	6 (4.6%)	0.273
<i>krusei</i>	3 (6.8%)	1 (1%)	0.05
others ¹	3 (6.8%)	3 (2.3%)	0.168
Co-Infection with <i>Aspergillus</i> , n (%)	1 (2.3%)	1 (0.8%)	0.441
Any pulmonary bacterial finding, n (%)	8 (18.2%)	53 (40.5%)	0.01
Gram positive	3 (6.8%)	13 (9.9%)	0.764
Gram negative	7 (15.9%)	45 (34.4%)	0.022
<i>E. Coli</i>	3 (6.8%)	9 (6.9%)	1
<i>Pseudomonas aeruginosa</i>	0 (0%)	7 (5.3%)	0.194
<i>Klebsiella pneumonia</i>	1 (2.3%)	5 (3.8%)	1
<i>Enterobacter species</i>	0 (0%)	4 (3.1%)	0.573
Others ²	3 (6.8%)	20 (15.3%)	0.2
<i>multi drug resistant pathogens</i>	0 (0%)	1 (0.8%)	1
Antifungal treatment, n (%)	17 (38.6%)		
Antibiotic treatment, n (%)	42 (96%)	92 (70.2%)	<0.001

¹ *Candida famata, lusitaniae* and *parapsilosis*.

² *Stenotrophomonas, Proteus mirabilis, Serratia marcescens, Citrobacter koseri, Actinetobacter baumannii, Proteus vulgaris, Citrobacter freundii, Morganella morgannii,*